Literature DB >> 2295322

Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

M S Bartlett1, J A Fishman, M M Durkin, S F Queener, J W Smith.   

Abstract

Rats which were immunosuppressed with adrenal corticosteroids then transtracheally inoculated with Pneumocystis carinii were evaluated as models for study of drug efficacy. Trimethoprim/sulfamethoxazole, known to be effective against Pneumocystis, was given in therapeutic and prophylactic regimens and its long-term effectiveness determined by a protocol to study relapse. Untreated animals uniformly developed severe infection with differences in numbers of organisms between untreated and treated animals being greater than two logs. Therapy of prophylaxis studies could be completed in 6 to 7 weeks. Animals given prophylaxis or therapy with trimethoprim/sulfamethoxazole had few organisms detected in lungs. Numbers of organisms did not increase during the 4 weeks when the animals were continued on immunosuppression after discontinuing treatment as long as reinfection was prevented. These models are useful for evaluating anti-Pneumocystis activity of antimicrobials. Relapse study data suggest that reinfection may have an important role in development of recurrent Pneumocystis pneumonia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295322     DOI: 10.1016/0014-4894(90)90089-u

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  20 in total

1.  Models for evaluating compounds for activity against Pneumocystis carinii.

Authors:  M S Bartlett
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

Review 2.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Phytosterols are present in Pneumocystis carinii.

Authors:  S T Furlong; J A Samia; R M Rose; J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 4.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.

Authors:  C J Boylan; W L Current
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

6.  Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.

Authors:  M C Broughton; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.

Authors:  L C Chio; L A Bolyard; M Nasr; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Effects of 8-aminoquinolines on the ultrastructural morphology of Pneumocystis carinii.

Authors:  M P Goheen; M S Bartlett; M M Shaw; S F Queener; J W Smith
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

9.  Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

Authors:  J A Fishman; S F Queener; R S Roth; M S Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

10.  Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.

Authors:  J C Comley; R J Mullin; L A Wolfe; M H Hanlon; R Ferone
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.